Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Brazil / NCT07313371
Recruiting Phase 4

Efficacy of Clonidine in Reducing Craving in Inpatients With Cocaine and Crack Use Disorder

NCT07313371 · tracked via the Priya Life Science Brazil tracker
Sponsor
University of Sao Paulo General Hospital
Phase
Phase 4
Started
2026-01-28
Last updated
2026-02-24

Condition(s) studied

Cocaine Use DisorderCrack Abuse or Dependence

Investigational drug(s) / intervention(s)

clonidine →clonazepam 0,25 mg →

clonidine: Clonidine 0,1 mg bid

clonazepam 0,25 mg: clonazepam 0,25 mg bid

Study summary

This is a single-center, randomized intervention study in a volunteer population of patients with cocaine/crack use disorder to evaluate the pharmacological treatment of cocaine/crack craving, comparing the drug clonidine with the active placebo clonazepam.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Patients hospitalized in the adult Alcohol and Drugs ward of the Perdizes Institute (IPer) at the Hospital das Clínicas, University of São Paulo Medical School * DSM-5 criteria for cocaine and/or crack use disorder * Voluntarily seeking treatment * Must be able to swallow pills Exclusion Criteria: * Inability to read and/or understand the study questionnaires * benzodiazepine use disorder * opioid use disorder * alcohol use disorder

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Instituto Perdizes São Paulo São Paulo Recruiting

More University of Sao Paulo General Hospital trials in Brazil

Sedentary Behavior and Depressive Symptoms Recruiting
Isolated Resistance Training and Neuromuscular Electrical Stimulation in Patients With Femoral Intra Aortic Balloon Pump. Recruiting
Effects of Elastic Tape on Pulmonary Rehabilitation of Patients with Chronic Obstructive Pulmonary Disease Recruiting
Evaluation by Clinical and Hand Ultrasound in Carpal Tunnel Syndrome Recruiting
Embolization in Hereditary Coagulopathies Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07313371 on ClinicalTrials.gov ↗ ← All trials in Brazil